Treatment with the mTOR inhibitor temsirolimus significantly inhibited the activation of mTOR effectors and reduced ESCC cell proliferation [135]; everolimus significantly inhibited angiotensin II-induced ESCC cell proliferation [136]. This evidence concerns the gene AGT and esophageal squamous cell carcinoma.